NEWCELX LTD
NCELNASDAQπ #4663 by market capEarnings Mar 3US Equity
$2.54βΌ $0.15 (β5.58%)
Market closed Β· at closeTrack NCEL
Get earnings, price moves & breaking news on Telegram
24hβΌ 5.6%
7dβΌ 7.1%
14dβΌ 5.9%
30dβΌ 10.6%
ytdβ² 25.1%
1yβΌ 26.4%
π¦Market Cap
$14M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $2.45 β $2.63
- 52-Week Range
- $1.83 β $5.12
- Volume (shares)
- 5,608
- Avg Volume (shares)
- β
- Shares Outstanding
- 5.4M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-1.33
- Dividend Yield
- β
- Dilution (1yr)
- +0.0%
NEWCELX LTD
NCELFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$2MβΌ β43.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$3MβΌ β35.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
3.4Mβ² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2Mβ² +$181K YoY
About NEWCELX LTD
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.